Appendix 4A

Statement of CDIs on issue

Information and documents given to ASX become ASX's property and may be made public.

*Denotes minimum information required for first lodgement of this form.

Part 1 – Entity and announcement details

| Question no | Question | Answer |
|----------------|--|--|
| 1.1 | *Name of entity We (the entity named above) provide the following information about our issued capital. ¹ | AVITA Therapeutics, Inc. ("Avita US") |
| 1.2 | *Registration type and number Please supply your ABN, ARSN, ARBN, ACN or another registration type and number (if you supply another registration type, please specify both the type of registration and the registration number). | ARBN 641 288 155 |
| 1.3 | *ASX issuer code | AVH |
| 1.4 | *The announcement is Tick whichever is applicable. | X New announcement Update/amendment to previous announcement Cancellation of previous announcement |
| 1.4a | *Reason for update Mandatory only if "Update" ticked in Q1.4 above. A reason must be provided for an update. | Not applicable |
| 1.4b | *Date of previous announcement to this update Mandatory only if "Update" ticked in Q1.4 above. | Not applicable |
| 1.4c | *Reason for cancellation Mandatory only if "Cancellation" ticked in Q1.4 above. | Not applicable |
| 1.4d | *Date of previous announcement to this cancellation Mandatory only if "Cancellation" ticked in Q1.4 above. | Not applicable |
| 1.5 | *Date of this announcement | 5 August 2020 |

1 December 2019

¹ Listing rule 4.11 requires an entity that has a dual listing on ASX and an overseas exchange and has CDIs issued over quoted securities, to complete an Appendix 4A and give it to ASX within 5 business days of the end of each month. An entity that has a dual listing on ASX and an overseas exchange and that is proposing to issue new equity securities and to have quoted CDIs over some or all of them, should notify ASX of the proposed issue of the underlying securities using an Appendix 3B and apply for the CDIs to be quoted using an Appendix 2A.

⁺ See chapter 19 for defined terms

Part 2 – Details of CDIs and other securities on issue

| Question No. | Question | | Answer | | | |
|-----------------|--|---|-----------------------------|--|--|--|
| 2.1 | *Statement for month and year Appendix 4A should be provided within 5 business days of the calendar month end, regardless of whether there is a change or not. | | Month: July Year: 2020 | | | |
| 2.2 | *Number and class of all ASX quoted CDIs on issue: Repeat the following information for each class of CDIs quoted on ASX | | | | | |
| | ASX security code: | Security description: | | CDI ratio ² : 5:1 | | |
| | Total number of CDIs quoted on ASX at end of statement month (A): 67,167,775 | Total number of CDIs quoted on ASX at end of previous month (B): 76,493,565 | | Net difference ³ (A-B): -9,325,790 | | |
| | Reason for change: | | | | | |
| | Please select the most appropriate underlying security description from the drop down list, and include details of the other exchange upon which the underlying securities are quoted. If the securities are not quoted on another exchange then state as location of the primary register. | | | | | |
| | Net transfers of securities between CDIs and | | Common stock | | | |
| | as quoted on | | The NASDAQ Stock Market LLC | | | |
| | If the total number of CDIs quoted on ASX at the end of the statement month (A), is greater than the total number of CDIs for which the entity has previously paid an initial listing fee or an additional listing fee under Table 1A and 1C of Guidance Note 15A (C), the entity hereby applies for +quotation of the difference (A – C) and agrees to the matters set out in Appendix 2A of the ASX Listing Rules. | | | | | |
| 2.3 | *Number and class of all issued securities not represented by CDIs quoted on ASX: Repeat the following table for each class of issued securities not represented (in whole or in part) by CDIs quoted on ASX | | | | | |
| | ASX security code: Not applicable | | | | | |
| | Total number of securities at end of statement month (A): | Total number of securities at end of previous month (B): | | Net difference (A-B): | | |
| | 8,034,939 | 6,169,199 | | 1,865,740 | | |
| | | | | | | |

² This is the ratio at which CDIs can be transmuted into the underlying security (e.g. 4:1 means 4 CDIs represent 1 underlying security whereas 1:4 means 1 CDI represents 4 underlying securities).

1 December 2019

³ The net difference should equal the number of underlying securities transmuted into CDIs during the month less the number of CDIs transmuted into underlying securities during the month

⁺ See chapter 19 for defined terms

| ASX security code: Not applicable | Security description: Unquoted options in AVITA Medical Limited ACN 28 058 466 523 (Avita Australia)* | | |
|--|---|--|--|
| Total number of securities at end of statement month (A): | Total number of securities at end of previous month (B): | Net difference (A-B): | |
| 125,966,172 (consolidated equivalent = 1,259,661 unquoted options in Avita US) | 126,052,414 (consolidated equivalent = 1,260,524 unquoted options in Avita US) | -86,242 (consolidated equivalent = 862 unquoted options in Avita US) | |
| | | | |

| ASX security code: Not applicable | Security description: Unquoted Restricted Stock Units in Avita Australia* | | |
|--|--|-----------------------|--|
| Total number of securities at end of statement month (A): | Total number of securities at end of previous month (B): | Net difference (A-B): | |
| 33,953,917 (consolidated equivalent = 339,359 unquoted restricted stock units in Avita US) | 33,935,917 (consolidated equivalent = 339,359 unquoted restricted stock units in Avita US) | 0 | |

*Note – the unquoted securities in Avita Australia (referred to above) entitle the holders of those securities, upon vesting of their conversion rights, to be issued shares of common stock in Avita US (which may be represented by Avita US CDIs) rather than shares in Avita Australia on a 100:1 consolidation ratio in accordance with, and pursuant to, their terms of issue and the deed poll entered into by Avita US on or about 6 May 2020 in favour of, amongst others, the holders of those securities.

Introduced 01/12/19